Risk of Venous Thromboembolism (VTE)

Lifestyle FactorsCurrent Medical StatusMedical History
Increasing age

Increasing COC use

Personal/Family history of VTE

SmokingPregnancy/PostpartumInherited blood clotting disorders
ObesityMajor surgeryCancer
Immobilisation & High AltitudeMajor traumaOther medical conditions associated with VTE
  • The risk of VTE is highest in first year of Combined Hormonal Contraceptive use.1,2
  • The risk of VTE is increased when a Combined Hormonal Contraceptive is re-started after a break in use of 4 weeks or more.1,2
  • Combined hormonal contraceptives that contain levonorgestrel, norgestimate or norethisterone are associated with the lowest risk of VTE.1,2  Zoely may have a risk of VTE in the same range as observed with combined hormonal contraceptives containing levonorgestrel.3

References:

  1. Faculty of Sexual & Reproductive Healthcare Statement Venous Thromboembolism (VTE) and Hormonal Contraception November 2014
  2. European Medicines Agency Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks – CHMP endorses PRAC recommendation November 2013 EMA/709120/2013
  3. Zoely® SPC Available at www.medicines.ie

Information placed on this digital platform is not intended as a substitute for consultation with your healthcare professional. Please consult your doctor or nurse for further information.

If you have a medical query about a Consilient Health medicine, please contact Consilient Health at drugsafety@consilienthealth.com or +353 (0)1 2057766.

For all other queries, please contact our Irish office at Tel: +353 (0) 1 2057760, Fax: +353 (0) 1 2698919 or irishoffice@consilienthealth.com or our Malta office at Tel: +356 22588600 or on email info@viviancorp.com.

Copyright ©2021 Consilient Health Ltd. All rights reserved.

The information on this website is intended for patients who have been prescribed Zoely that reside in the Republic of Ireland or Malta only.

IE-ZOE-23(3) | Date of preparation: June 2022